Epigenomics AG / Key word(s): Corporate Action/AGM/EGM
09-Sep-2022 / 19:19 CET/CEST
Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
Berlin, September 9, 2022 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) plans to propose to the extraordinary Shareholders’ Meeting, which is to be convened on October 21, 2022 and conducted as a virtual general meeting without physical presence of the Shareholders or their proxies, in addition to the notification of loss pursuant to Section 92 par. 1 AktG, the reduction of the share capital to a quarter of the share capital at the time of the Shareholders’ Meeting.
The capital reduction is to take place in two steps. First, the share capital shall be reduced by withdrawing up to three treasury shares acquired free of charge so that the share capital is a multiple of four. Secondly, the share capital of the Company shall be reduced to a quarter by means of an ordinary capital reduction in accordance with Section 222 et seq. AktG. The ordinary capital reduction shall be carried out by combining the shares of the Company in the ratio 4 : 1 and serves partly to cover losses and partly to allocate to the Company’s capital reserves.
The specific amount of the capital reduction depends on amount of share capital as of the date of the extraordinary Shareholders’ Meeting on 21 October 2022 which in turn depends on whether and to what extent the holders of the convertible bonds issued by the Company exercise their conversion rights in the conversion window at the beginning of October 2022. Based on the share capital as of today in the amount of EUR 16,357,482.00 the share capital would be reduced by EUR 2.00 to EUR 16,357,480.00 by withdrawing shares and then by EUR 12,268,110.00 to EUR 4,089,370.00 by combining shares.
The complete agenda, together with explanations and more detailed information on registration for the extraordinary General Shareholders’ Meeting, can be found in the invitation, which is expected to be published in the Federal Gazette on September 14, 2022 and will also be available at https://www.epigenomics.com/news-investors/general-shareholder-meeting/.
Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: firstname.lastname@example.org
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: email@example.com
Note on forward-looking statements
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
|Phone:||+49 30 24345-0|
|Fax:||+49 30 24345-555|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1439733|
|End of Announcement||DGAP News Service|